Masimo starts public life with sharp rise:
This article was originally published in Clinica
Executive Summary
Pulse oximetry company Masimo has closed its initial public offering of around 12 million shares and began life on the Nasdaq on August 8. The Irvine, California-based firm saw its share price increase by 9% on the first day of trading to $20.90 per share from $19 per share. The company has sustained this high rise since, as shares were priced at $21 at the close of markets on August 13. Masimo intends to use proceeds from the IPO to further commercialisation of its Masimo SET and Masimo Rainbow SET products - monitoring technologies which the company claims are proven to allow clinicians to accurately monitor blood oxygen saturation in critical situations by clinical and laboratory studies.
You may also be interested in...
EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: